Podcasts about agaf

Guest: Thomas DeLoughery, MD Host: Peter Buch, MD, FACG, AGAF, FACP Iron deficiency anemia is common in gastroenterology patients and is often underrecognized or suboptimally managed. That's why targeted treatment is essential to improve patient outcomes. In this expert-led discussion, Dr. Peter Buch and Dr. Thomas DeLoughery outline what gastroenterologists need to know about oral vs IV iron, absorption dynamics, and tailoring therapy for various patient populations. Dr. DeLoughery is a Professor of Medicine in the Division of Hematology and Oncology at Oregon Health and Science University in Portland.

Guest: Francis Farraye, MD Host: Peter Buch, MD, FACG, AGAF, FACP A 2025 update to the American College of Gastroenterology (ACG)'s guideline on preventive care in inflammatory bowel disease (IBD) includes key changes impacting vaccine recommendations, dermatologic screening, and care coordination. Dr. Peter Buch sits down with Dr. Francis Farraye, lead author of this guideline, to highlight what clinicians need to know. Dr. Farraye is a Professor of Medicine and the Director of the Inflammatory Bowel Disease Center at the Mayo Clinic in Jacksonville, Florida

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Iris Wang, M.D. From symptom trackers to multidisciplinary app-based platforms, evidence-based digital therapeutics are expanding access to brain-gut behavioral care for patients with irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Dr. Peter Buch sits down with Dr. Iris Wang to discuss the spectrum of available tools and explore strategies for aligning them with individual patient needs. Dr. Wang is an Associate Professor of Medicine and the Associate Program Director of the Gastroenterology Fellowship at the Mayo Clinic in Rochester, Minnesota.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC information, and to apply for credit, please visit us at PeerView.com/SCH865. CME/MOC/CC credit will be available until August 26, 2026.Beyond the Eosinophil: Mastering the Complexities of EoE Diagnosis In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Rodger C. Haggitt Gastrointestinal Pathology Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC information, and to apply for credit, please visit us at PeerView.com/SCH865. CME/MOC/CC credit will be available until August 26, 2026.Beyond the Eosinophil: Mastering the Complexities of EoE Diagnosis In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Rodger C. Haggitt Gastrointestinal Pathology Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC information, and to apply for credit, please visit us at PeerView.com/SCH865. CME/MOC/CC credit will be available until August 26, 2026.Beyond the Eosinophil: Mastering the Complexities of EoE Diagnosis In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Rodger C. Haggitt Gastrointestinal Pathology Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC information, and to apply for credit, please visit us at PeerView.com/SCH865. CME/MOC/CC credit will be available until August 26, 2026.Beyond the Eosinophil: Mastering the Complexities of EoE Diagnosis In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Rodger C. Haggitt Gastrointestinal Pathology Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Neena Abraham, MD, MS Knowing how to manage anticoagulants and antithrombotics during acute GI bleeding is essential in preventing avoidable complications, including thromboembolism and delayed hemostasis. Dr. Peter Buch sits down with Dr. Neena Abraham to discuss the latest recommendations from major GI and cardiology societies and explore practical strategies for anticoagulant reversal, triage criteria, and endoscopic hemostasis. Dr. Abraham is a Professor of Medicine and the Medical Director of the Cardiogastroenterology Clinic at the Mayo Clinic in Phoenix.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VJH865. CME/NCPD/CPE/AAPA/IPCE credit will be available until August 17, 2026.Transforming PBC Management: Targeted Relief and Improved Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Ipsen Biopharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VJH865. CME/NCPD/CPE/AAPA/IPCE credit will be available until August 17, 2026.Transforming PBC Management: Targeted Relief and Improved Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Ipsen Biopharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VJH865. CME/NCPD/CPE/AAPA/IPCE credit will be available until August 17, 2026.Transforming PBC Management: Targeted Relief and Improved Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Ipsen Biopharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VJH865. CME/NCPD/CPE/AAPA/IPCE credit will be available until August 17, 2026.Transforming PBC Management: Targeted Relief and Improved Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Ipsen Biopharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VJH865. CME/NCPD/CPE/AAPA/IPCE credit will be available until August 17, 2026.Transforming PBC Management: Targeted Relief and Improved Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Ipsen Biopharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VJH865. CME/NCPD/CPE/AAPA/IPCE credit will be available until August 17, 2026.Transforming PBC Management: Targeted Relief and Improved Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Ipsen Biopharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VJH865. CME/NCPD/CPE/AAPA/IPCE credit will be available until August 17, 2026.Transforming PBC Management: Targeted Relief and Improved Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Ipsen Biopharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VJH865. CME/NCPD/CPE/AAPA/IPCE credit will be available until August 17, 2026.Transforming PBC Management: Targeted Relief and Improved Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Ipsen Biopharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Trauma isn't just in your mind—it can live in your body, shaping how your gut feels and functions.   On this episode of The Gut Show I talk to @drriehl from @theguthealthpodcast and we explore what trauma is, how it connects to IBS, feelings of hopelessness and options for treatment.    Mentioned in this episode:  Tailored to the Core: Breathing, Bloating and Precision Medicine: https://www.buzzsprout.com/2293918/episodes/17382514 Poop Personality Quiz: https://quiz.tryinteract.com/#/657789ba420624001409ca1a   MASTER Method Membership: https://www.ibsmastermethod.com/master-method     About our guest:  Dr. Megan Riehl, PsyD, AGAF is an Associate Professor of Medicine at the University of Michigan and a leading expert in psychogastroenterology. With a full-time clinical practice, she specializes in GI behavioral health, providing patient care, peer consultation, and professional training. Dr. Riehl also holds key leadership roles within Michigan Medicine focused on the area of wellbeing. A recognized thought leader, she serves on the national Board of Trustees for the Crohn's and Colitis Foundation. She is also the co-author of Mind Your Gut: The Science-Based, Whole-Body Guide to Living Well with IBS and co-host of The Gut Health Podcast alongside Kate Scarlata.   Mind Your Gut: https://amzn.to/3Ji96HB GI Psychology: www.gipsychology.com Psychology Today: www.psychologytoday.com  The Gut Health Podcast: https://theguthealthpodcast.buzzsprout.com     Thank you to our partners: This episode is made possible with support from Ardelyx. @gemellibiotech offers trusted, science-backed at-home tests for conditions like SIBO, IMO, ISO, and post-infectious IBS.  Their Trio-Smart breath test measures all three key gases: hydrogen, methane, and hydrogen sulfide to detect different forms of microbial overgrowth. And for those with IBS symptoms, IBS-Smart is a simple blood test that can confirm post-infectious IBS with clinical accuracy. You simply order the test, complete it at home, send it back, and get clinically backed results in about a week that you can take to your provider!  Find out which tests are right for you at getgutanswers.com and use code ERINJUDGE25 to save $35 on your order! @fodzyme is the world's first enzyme supplement specialized to target FODMAPs. When sprinkled on or mixed with high-FODMAP meals, FODZYME's novel patent-pending enzyme blend breaks down fructan, GOS and lactose before they can trigger bloating, gas and other digestive issues. With FODZYME, enjoy garlic, onion, wheat, Brussels sprouts, beans, dairy and more — worry free! Discover the power of FODZYME's digestive enzyme blend and eat the foods you love and miss. Visit fodzyme.com and save 20% off your first order with code THEGUTSHOW. One use per customer.    

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michael Camilleri, MD GLP-1 receptor agonists are revolutionizing treatment for diabetes and obesity, but their impact on the gastrointestinal tract demands careful clinical attention. Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine at the Mayo Foundation for Medical Education and Research in Rochester, Minnesota, to discuss key findings on gastrointestinal side effects, procedural risks, and the impacts of GLP-1 receptor agonists on the fields of gastroenterology and hepatology.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michael Camilleri, MD GLP-1 receptor agonists are revolutionizing treatment for diabetes and obesity, but their impact on the gastrointestinal tract demands careful clinical attention. Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine at the Mayo Foundation for Medical Education and Research in Rochester, Minnesota, to discuss key findings on gastrointestinal side effects, procedural risks, and the impacts of GLP-1 receptor agonists on the fields of gastroenterology and hepatology.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Ashwani K. Singal MD, MS, FACG, FAASLD, AGAF Sarcopenia and poor nutrition are often silent threats in chronic liver disease, yet they drastically impact outcomes. Joining Dr. Peter Buch to discuss strategies for recognizing and addressing malnutrition early to improve long-term liver health is Dr. Ashwani Singal. Dr. Singal is a Professor of Medicine at the University of Louisville School of Medicine.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Ashwani K. Singal MD, MS, FACG, FAASLD, AGAF Sarcopenia and poor nutrition are often silent threats in chronic liver disease, yet they drastically impact outcomes. Joining Dr. Peter Buch to discuss strategies for recognizing and addressing malnutrition early to improve long-term liver health is Dr. Ashwani Singal. Dr. Singal is a Professor of Medicine at the University of Louisville School of Medicine.

How do you decide when to move from first-line to second-line treatment for primary biliary cholangitis (PBC)? In this podcast, listen as experts Alan Bonder, MD, AGAF, and Aparna Goel, MD, discuss this question and more, including:How and when to measure treatment responseEvidence-based goals of therapyConsiderations for second-line treatmentNew agents for second-line treatment: PPAR agonistsPresenters:Alan Bonder, MD, AGAFAssociate Professor of MedicineMedical Director of Liver TransplantDepartment of GastroenterologyBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsAparna Goel, MDAssociate Clinical Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaContent based on an online CME program supported by independent educational grants from Gilead Sciences, Inc., and Ipsen Biopharmaceuticals, Inc​.To learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.Supported by educational grants from Gilead Sciences, Inc. and Ipsen Biopharmaceuticals, Inc

In this podcast, listen as experts Alan Bonder, MD, AGAF, and Aparna Goel, MD, discuss how they assess the symptoms of primary biliary cholangitis (PBC) and explore how new therapeutic agents may help alleviate symptom burden. Topics include:Strategies and tools for assessing pruritusNonpharmacologic and pharmacologic management of pruritusSecond-line agents and their impact on pruritusInvestigational treatments for pruritusPresenters:Alan Bonder, MD, AGAFAssociate Professor of MedicineMedical Director of Liver TransplantDepartment of GastroenterologyBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsAparna Goel, MDAssociate Clinical Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaContent based on an online CME program supported by independent educational grants from Gilead Sciences, Inc., and Ipsen Biopharmaceuticals, Inc​.To learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: David Fudman, MD As the advanced treatment landscape for inflammatory bowel disease continues to expand, selecting the right therapies has become more complex, with efficacy, safety, patient preferences, disease phenotypes, and more as factors to consider. Learn how to effectively navigate these therapeutic options for ulcerative colitis and Crohn's disease with Dr. Peter Buch and Dr. David Fudman, Assistant Professor and Director of Inflammatory Bowel Disease Clinics at the University of Texas Southwestern Medical Center.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: David Fudman, MD As the advanced treatment landscape for inflammatory bowel disease continues to expand, selecting the right therapies has become more complex, with efficacy, safety, patient preferences, disease phenotypes, and more as factors to consider. Learn how to effectively navigate these therapeutic options for ulcerative colitis and Crohn's disease with Dr. Peter Buch and Dr. David Fudman, Assistant Professor and Director of Inflammatory Bowel Disease Clinics at the University of Texas Southwestern Medical Center.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Stefan Holubar, MD, MS When are ostomies necessary in patients with inflammatory bowel disease? Join Dr. Peter Buch and Dr. Stefan Holubar, Director of Research at the IBD Surgery Section at the Cleveland Clinic, as they explore key surgical considerations for both ulcerative colitis and Crohn's disease, including when to consider temporary versus permanent ileostomies, how to manage complications like anastomotic leaks, and what factors influence the decision to delay or avoid ileal pouch creation.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Stefan Holubar, MD, MS When are ostomies necessary in patients with inflammatory bowel disease? Join Dr. Peter Buch and Dr. Stefan Holubar, Director of Research at the IBD Surgery Section at the Cleveland Clinic, as they explore key surgical considerations for both ulcerative colitis and Crohn's disease, including when to consider temporary versus permanent ileostomies, how to manage complications like anastomotic leaks, and what factors influence the decision to delay or avoid ileal pouch creation.

In this podcast episode, Ryan Stidham, MD, discusses the evolution and development of digital imaging and AI in the GI space, how AI can revolutionize stages within the clinical trials and practices and more. •    Intro :24 •    The interview/about Stidham :36 •    Tell us about your family and where you grew up. 1:14 •    How did you embrace changes in technology growing up? 3:07 •    What was the seminal moment that got you to move from being a consumer of information to being a producer and innovator?  6:05 •    What ignited you to start commercializing and patenting your ideas, and operationalizing them into a company? How did that evolution occur? 8:32 •    Can you give a quick overview of what these tools and technologies entail?  12:52 •    What got you interested in inflammatory bowel disease, and how did your childhood interest in coding shift to artificial intelligence? 18:12 •    Where did your interest in AI come about? 20:26 •    You recently published a review on how AI will revolutionize the conduct of clinical trials in inflammatory bowel disease […] Will AI remove the need for central reading in IBD trials in the future? 23:58 •    How do we change the way we train GI doctors, and should we start making these changes today? 26:38 •    With AI rapidly changing the landscape, are we spending enough time educating our fellows in how to adapt to changes and communicate with patients? 32:33 •    What do you think will change in IBD and gastroenterology in the near term as a result of AI? 35:06 •    What is it that we really need in terms of health care access, and how can AI technology assist these needs? 38:39 •    Thank you, Ryan 44:04 •    Thanks for listening 44:20 Ryan Stidham, MD, MS, AGAF, is a translational scientist caring exclusively for patients with inflammatory bowel disease. He is an associate professor in the department of medicine and the department of computational medicine and bioinformatics where he serves as the associate chair of translational research. His research focus is the use of artificial intelligence to improving measurement of IBD and other gastrointestinal diseases, developing new interpretations of cross-sectional imaging, endoscopy, medical text, and other electronic data.  We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more from Stidham, follow @CrohnsDoc on X. Disclosures: Berry and Chey report no relevant financial disclosures. Stidham reports consulting or on advisory boards for AbbVie, Bristol Myers Squibb, CorEvitas, Eli Lilly, Exact Sciences, Gilead, Janssen, Merck, Pfizer, and Takeda. Stidham holds intellectual property and equity on medical imaging and endoscopic analysis technologies licensed by the University of Michigan to PreNovo, LLC, AMI, LLC and PathwaysGI, Inc.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Mark Benson, MD Colonic perforations during colonoscopy are rare, but when they occur, taking swift and informed action is critical, particularly to avoid surgical intervention. Joining Dr. Peter Buch to offer his insights on perforation prevention, risk-reduction techniques, and repair strategies is Dr. Mark Benson, an advanced endoscopist and Associate Professor in the Division of Gastroenterology and Hepatology at the University of Wisconsin School of Medicine.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Mark Benson, MD Colonic perforations during colonoscopy are rare, but when they occur, taking swift and informed action is critical, particularly to avoid surgical intervention. Joining Dr. Peter Buch to offer his insights on perforation prevention, risk-reduction techniques, and repair strategies is Dr. Mark Benson, an advanced endoscopist and Associate Professor in the Division of Gastroenterology and Hepatology at the University of Wisconsin School of Medicine.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: J. Andy Tau, MD Topical hemostatic agents play a key role in managing complex bleeding cases, but there's a lot to keep in mind when selecting which agent to use, like their mechanism and efficacy. Joining Dr. Peter Buch to share top considerations and best practices for using topical hemostatic agents is Dr. J Andy Tau, a board-certified gastroenterologist at Austin Gastroenterology in Texas.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: J. Andy Tau, MD Topical hemostatic agents play a key role in managing complex bleeding cases, but there's a lot to keep in mind when selecting which agent to use, like their mechanism and efficacy. Joining Dr. Peter Buch to share top considerations and best practices for using topical hemostatic agents is Dr. J Andy Tau, a board-certified gastroenterologist at Austin Gastroenterology in Texas.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Aasma Shaukat, MD, MPH While fecal immunochemical testing and multitarget stool DNA testing are commonly used to screen for colon cancer, screening rates remain low throughout the United States. With the introduction of blood-based testing modalities, noninvasive colon cancer screening is becoming more accessible than ever. Join host Dr. Peter Buch and Dr. Aasma Shaukat as they discuss the effectiveness of current and emerging methods as well as best practices for screening patients. Dr. Shaukat is the Robert M. and Mary H. Glickman Professor of Medicine at the NYU Grossman School of Medicine and the Co-Director of Translational Research, Education, and Careers and the Director of Outcomes Research in the Division of Gastroenterology and Hepatology at NYU.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Aasma Shaukat, MD, MPH While fecal immunochemical testing and multitarget stool DNA testing are commonly used to screen for colon cancer, screening rates remain low throughout the United States. With the introduction of blood-based testing modalities, noninvasive colon cancer screening is becoming more accessible than ever. Join host Dr. Peter Buch and Dr. Aasma Shaukat as they discuss the effectiveness of current and emerging methods as well as best practices for screening patients. Dr. Shaukat is the Robert M. and Mary H. Glickman Professor of Medicine at the NYU Grossman School of Medicine and the Co-Director of Translational Research, Education, and Careers and the Director of Outcomes Research in the Division of Gastroenterology and Hepatology at NYU.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FEE865. CME/NCPD/AAPA/IPCE credit will be available until March 9, 2026.Innovative Approaches to Manage Primary Biliary Cholangitis: Charting New Courses of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Ipsen Biopharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FEE865. CME/NCPD/AAPA/IPCE credit will be available until March 9, 2026.Innovative Approaches to Manage Primary Biliary Cholangitis: Charting New Courses of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Ipsen Biopharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FEE865. CME/NCPD/AAPA/IPCE credit will be available until March 9, 2026.Innovative Approaches to Manage Primary Biliary Cholangitis: Charting New Courses of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Ipsen Biopharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FEE865. CME/NCPD/AAPA/IPCE credit will be available until March 9, 2026.Innovative Approaches to Manage Primary Biliary Cholangitis: Charting New Courses of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Ipsen Biopharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FEE865. CME/NCPD/AAPA/IPCE credit will be available until March 9, 2026.Innovative Approaches to Manage Primary Biliary Cholangitis: Charting New Courses of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Ipsen Biopharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FEE865. CME/NCPD/AAPA/IPCE credit will be available until March 9, 2026.Innovative Approaches to Manage Primary Biliary Cholangitis: Charting New Courses of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Ipsen Biopharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

In this episode, Patricia D. Jones, MD, MSCR; Mindie H. Nguyen, MD, MAS, AGAF, FAASLD; and patient advocate, Jennifer Wild, MS, RN, OCN, discuss practical strategies to overcome barriers to hepatitis B virus (HBV) care, including: Overcoming health insurance navigation Improving access to HBV care in immigrant communitiesDispelling HBV myths and stigmaSolutions to language barriersCommunity-based interventionsPresenters:Patricia D. Jones, MD, MSCRAssociate Professor of Clinical MedicineDirector of Clinical Operations-HepatologyDivision of Digestive Health and Liver DiseasesDepartment of MedicineUniversity of Miami Miller School of MedicineSylvester Comprehensive Cancer CenterMiami, FloridaMindie H. Nguyen, MD, MAS, AGAF, FAASLDProfessor of Medicine (GI & Hepatology,Liver Transplant)Professor of Epidemiology & Population Health(by Courtesy)Director of Hepatology ClerkshipFaculty Search LENS Advocates,Stanford Department of MedicineFaculty Fellow, Stanford Center for Innovationin Global HealthMember, Stanford Cancer Institute, Maternal &Child Health Research Institute, & Stanford Bio-CStanford, CaliforniaPast Chair: HBV SIG, The American Association for the Study of Liver Diseases (AASLD)28th President: The International Association for the Study of the Liver (IASL)Jennifer Wild, MS, RN, OCNClinical Nurse – GI Medical OncologyUCSF Cancer CenterSan Francsico, CaliforniaLink to full program: https://bit.ly/4j973TNDownloadable slides: https://bit.ly/3WQkIWlGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

How do you decide when to move from first-line to second-line treatment for primary biliary cholangitis (PBC)? In this podcast, listen as experts Alan Bonder, MD, AGAF, and Aparna Goel, MD, discuss this question and more, including:How and when to measure treatment responseEvidence-based goals of therapyConsiderations for second-line treatmentNew agents for second-line treatment: PPAR agonistsPresenters:Alan Bonder, MD, AGAFAssociate Professor of MedicineMedical Director of Liver TransplantDepartment of GastroenterologyBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsAparna Goel, MDAssociate Clinical Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaContent based on an online CME program supported by independent educational grants from Gilead Sciences, Inc., and Ipsen Biopharmaceuticals, Inc​.To learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.Supported by educational grants from Gilead Sciences, Inc. and Ipsen Biopharmaceuticals, Inc

In this podcast, listen as experts Alan Bonder, MD, AGAF, and Aparna Goel, MD, discuss how they assess the symptoms of primary biliary cholangitis (PBC) and explore how new therapeutic agents may help alleviate symptom burden. Topics include:Strategies and tools for assessing pruritusNonpharmacologic and pharmacologic management of pruritusSecond-line agents and their impact on pruritusInvestigational treatments for pruritusPresenters:Alan Bonder, MD, AGAFAssociate Professor of MedicineMedical Director of Liver TransplantDepartment of GastroenterologyBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsAparna Goel, MDAssociate Clinical Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaContent based on an online CME program supported by independent educational grants from Gilead Sciences, Inc., and Ipsen Biopharmaceuticals, Inc​.To learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.

In this episode, Patricia D. Jones, MD, MSCR; Mindie H. Nguyen, MD, MAS, AGAF, FAASLD; and patient advocate, Jennifer Wild, MS, RN, OCN, discuss best practices in hepatitis B virus (HBV) care, including: 2023 CDC HBV screening recommendationsSummary of guideline recommendations for hepatitis delta virus (HDV) screening Use of HDV reflex testing to avoid loss to follow-up2024 WHO HBV treatment recommendations, including recommendations for pregnant persons Presenters:Patricia D. Jones, MD, MSCRAssociate Professor of Clinical MedicineDirector of Clinical Operations-HepatologyDivision of Digestive Health and Liver DiseasesDepartment of MedicineUniversity of Miami Miller School of MedicineSylvester Comprehensive Cancer CenterMiami, FloridaMindie H. Nguyen, MD, MAS, AGAF, FAASLDProfessor of Medicine (GI & Hepatology,Liver Transplant)Professor of Epidemiology & Population Health(by Courtesy)Director of Hepatology ClerkshipFaculty Search LENS Advocates,Stanford Department of MedicineFaculty Fellow, Stanford Center for Innovationin Global HealthMember, Stanford Cancer Institute, Maternal &Child Health Research Institute, & Stanford Bio-CStanford, CaliforniaPast Chair: HBV SIG, The American Association for the Study of Liver Diseases (AASLD)28th President: The International Association for the Study of the Liver (IASL)Jennifer Wild, MS, RN, OCNClinical Nurse – GI Medical OncologyUCSF Cancer CenterSan Francsico, CaliforniaLink to full program: https://bit.ly/4j973TNDownloadable slides: https://bit.ly/3WQkIWlGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Vivek Kaul, MD The American Society for Gastrointestinal Endoscopy (ASGE) recently released a new guideline on when to use endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR) in managing early esophageal and gastric cancers. To learn more about when to use each approach, Dr. Peter Buch sits down with guideline co-author Dr. Vivek Kaul. Dr. Kaul is also the Segal-Watson Professor of Medicine at the University of Rochester Medical Center in New York.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: William Chey, MD Recent changes to the American College of Gastroenterology's guidelines on H. pylori treatment provide recommendations for antibiotic susceptibility and optimal patient management. Dr. Peter Buch sits down with the lead author of these guidelines, Dr. William Chey, to learn more about implications for clinical practice. Dr. Chey is the Chief of the Division of Gastroenterology and Hepatology, the H. Marvin Pollard Professor of Gastroenterology, and a Professor of Nutrition Sciences at the University of Michigan.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Vivek Kaul, MD The American Society for Gastrointestinal Endoscopy (ASGE) recently released a new guideline on when to use endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR) in managing early esophageal and gastric cancers. To learn more about when to use each approach, Dr. Peter Buch sits down with guideline co-author Dr. Vivek Kaul. Dr. Kaul is also the Segal-Watson Professor of Medicine at the University of Rochester Medical Center in New York.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: William Chey, MD Recent changes to the American College of Gastroenterology's guidelines on H. pylori treatment provide recommendations for antibiotic susceptibility and optimal patient management. Dr. Peter Buch sits down with the lead author of these guidelines, Dr. William Chey, to learn more about implications for clinical practice. Dr. Chey is the Chief of the Division of Gastroenterology and Hepatology, the H. Marvin Pollard Professor of Gastroenterology, and a Professor of Nutrition Sciences at the University of Michigan.

In this podcast episode, Larry Kosinski, MD, founder of SonarMD, discusses reclaiming GI services for patients and physicians, developing new tools for IBD patients and more. •    Intro :24 •    The interview/about Kosinski :29 •    Can you tell us about your upbringing and the experiences that got you to where you are today? What got you interested in gastroenterology? :55 •    Of the many “chapters” in your story, can you talk about your merger and acquisition experience in the medical field? How has the process of different GI groups coming together changed over time? 5:40 •    Why did the investors of SonarMD want to confine activities to just IBD and not scale it?  20:49 •    Chey and Kosinski on the issues of moving away from patients being at the center of the decision-making and equal partnership in mergers and acquisitions. 22:03 •    Chey and Kosinski on what drives physician burnout in gastroenterology.  25:06 •    Do you feel that solutions focused on addressing cost in IBD is going to be as effective as solutions in addressing costs associated with functional diseases? 28:02 •    What do you see next for SonarMD, and how has your own transition into your next “chapter” been? 32:24 •    Berry, Chey and Kosinski on the development of tools to assist patients with IBD and diagnose GI conditions. 40:10 •    What have you learned from the different projects you have worked on, and what advice would you give gastroenterologists interested in this type of innovation? 42:20 •    Thank you, Larry 44:09 •    Thanks for listening 44:33 Lawrence R. Kosinski, MD, MBA, AGAF, FACG, is a retired gastroenterologist who practiced for 35 years in suburban Chicago and is one of the founders of Illinois Gastroenterology Group, the largest independent GI practice in Illinois. We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more from Kosinski, follow @lrkosinski on X. Disclosures: Berry, Chey and Kosinski report no relevant financial disclosures. 

Immunotherapy and targeted therapies have transformed the way patients are treated and allow more patients than ever before to survive stage IV diagnoses. Other key advancements in oncology being prioritized in Puerto Rico today include early detection and prevention efforts. However, a lack of education, access, and health insurance coverage often prevents community members from timely cancer screenings. The same factors contribute to a lack of diversity in clinical trials, as noted by Dr. Marcia Cruz-Correa. Both these important issues require a community-based approach, through building advisory groups, working with local oncologists, and reaching community members where they are in a way they understand. Guest:  Marcia Cruz-Correa, MD, PhD, AGAF, FASGEExecutive DirectorCentro Comprensivo de Cáncer de la Universidad de PuertoSan Juan, Puerto Rico Quote:  “Less than 5% of patients in the US participate in clinical trials...and less than 5% of that [group] is diverse. That's a huge disadvantage...If you don't include the patients who will eventually be taking the drugs developed by pharmaceutical companies, how do you know it will work for them?” Read more global perspectives from the international panelists who spoke at the October ACCC 41st National Oncology Conference in this ACCCBuzz blog. Additional Resources:  Bridging the Gap: Early Detection of Cancer for the Medically Underserved – Oncology Issues Effective Patient-Provider Communication for Colorectal Cancer Screening Multi-Cancer Early Detection: Legislative Landscape— [PODCAST] EP 99 Examining Clinical Research for Patients with Acute Myeloid Leukemia 2023 NMQF Summit: Improving Diversity in Cancer Clinical Trials